Is this you? Create Your Porfile
Avatar

Darren Mark Legrand

Novartis

Network

Latest external collaboration on country level. Dive into details by clicking on the dots.

Explore More

Hotspot

Dive into the research topics where Darren Mark Legrand is active.

Explore More

Publication

Featured researches published by Darren Mark Legrand.

Bioorganic & Medicinal Chemistry Letters | 2000

the design and synthesis of thrombin inhibitors: the introduction of in vivo efficacy and oral bioavailability into benzthiazolylalanine inhibitors

Judy Hayler; Peter Kane; Darren Mark Legrand; Florence Lugrin; Keith Menear; Richard Price; Mark C. Allen; Xiao-Ling Fan Cockcroft; John Ambler; Keith Butler; Karren Dunnet; Andrew Mitchelson; Mark Talbot; Morris Tweed; Nicholas Wills

The further optimisation of the novel lead compound CGH752 (Fig. 1) is described. By introducing various substituents into the 6-position of the 3,3-dimethyltetrahydroquinoline (DMTHQS) ring we have been able to favourably affect the in vitro and in vivo activity, and the pharmacokinetics of such compounds. One of the inhibitors synthesised (CGH1484) is bioavailable and shows efficacy in animal models of thrombosis.

Archive | 2008

PI 3-KINASE INHIBITORS AND METHODS OF THEIR USE

Zhi-Jie Ni; Sabina Pecchi; Matthew Burger; Wooseok Han; Aaron Smith; Gordana Atallah; Sarah Bartulis; Kelly Frazier; Joelle Verhagen; Yanchen Zhang; Edwin Iwanowicz; Tom Hendrickson; Mark Knapp; Hanne Merritt; Charles Voliva; Marion Wiesmann; Darren Mark Legrand; Ian Bruce; James Dale; Jiong Lan; Barry H. Levine; Abran Costales; Jie Liu; Teresa Pick; Daniel Menezes

Archive | 2011

Pyridine and pyrazine derivative for the treatment of CF

Urs Baettig; Kamlesh Jagdis Bala; Emma Budd; Lee Edwards; Catherine Howsham; Glyn Hughes; Darren Mark Legrand; Katrin Spiegel

Archive | 2012

N-substituted heterocyclyl carboxamides

Kamlesh Jagdis Bala; Emma Budd; Lee Edwards; Catherine Howsham; Darren Mark Legrand; Roger John Taylor

Archive | 2006

Pyrazine derivatives as epithelial sodium channel blocker

Stephen Paul Collingwood; Nichola Smith; Brian Cox; Darren Mark Legrand

Archive | 2012

Heterocyclic compounds for the treatment of cystic fibrosis

Kamlesh Jagdis Bala; Rebecca Butler; Stephen Paul Collingwood; Edward Charles Hall; Lee Edwards; Darren Mark Legrand; Katrin Spiegel

Archive | 2007

5-PHENYL-THIAZOL-2-YL-UREA DERIVATIVES AND USE AS PI3 KINASE INHIBITORS

Emma Budd; Judy Hayler; Ian Bruce; Darren Mark Legrand; Brian Cox

Archive | 2007

5-PHENYL-THIAZ0L-2-YL-UREA DERIVATIVES AND USE AS PI3 KINASE INHIBITORS

Emma Budd; Judy Hayler; Ian Bruce; Darren Mark Legrand; Brian Cox

Archive | 2014

Autotaxin inhibitors comprising a heteroaromatic ring-benzyl-amide-cycle core

David Beattie; Urs Baettig; Darren Mark Legrand; Andrew Stuart Lister; Jeffrey Mckenna; David William Pearce; David Andrew Sandham; Oliver Ross Steward; Christopher Thomson

Archive | 2012

Heterocyclic Compounds for the Treatment of CF

Kamlesh Jagdis Bala; Rebecca Butler; Stephen Paul Collingwood; Edward Charles Hall; Lee Edwards; Darren Mark Legrand; Katrin Spiegel

Explore More

Collaboration

Dive into the Darren Mark Legrand's collaboration.

Top Co-Authors
Avatar

Emma Budd

Novartis

View shared research outputs
Top Co-Authors
Avatar

Kamlesh Jagdis Bala

Novartis

View shared research outputs
Top Co-Authors
Avatar

Urs Baettig

Novartis

View shared research outputs
Top Co-Authors
Avatar

Catherine Howsham

Novartis

View shared research outputs
Top Co-Authors
Avatar

Katrin Spiegel

Novartis

View shared research outputs
Top Co-Authors
Avatar

Lee Edwards

Novartis

View shared research outputs
Top Co-Authors
Avatar

Christopher Thomson

Novartis

View shared research outputs
Top Co-Authors
Avatar

Glyn Hughes

Novartis

View shared research outputs
Top Co-Authors
Avatar

Ian Bruce

Novartis

View shared research outputs
Top Co-Authors
Avatar

Judy Hayler

Novartis

View shared research outputs
Explore More
Researchain Logo
Decentralizing Knowledge